Short Implants in Edentulous Mandible

NCT ID: NCT04838184

Last Updated: 2021-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-04-19

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Main aim of this study was to assess survival rates of short implants with a length of 4 mm in the edentulous mandible after 1, 3, and 5 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is hypothesized that survival rates after 1, 3, and 5 years of Straumann Roxolid® / SLActive® 4 mm short implants do not differ from values of Straumann SLActive implants with more than 4 mm length in the same clinical situation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tooth Loss Edentulous Jaw

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dental patients

Patients with an edentulous mandible who are demanding and receiving an implant-supported fixed dental prosthesis in the mandible

Dental Implants (Straumann Roxolid® / SLActive®)

Intervention Type DEVICE

In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.

In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dental Implants (Straumann Roxolid® / SLActive®)

In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.

In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

General criteria:

* Age: 18 to 70
* Edentulous mandible with reduced bone level in the posterior region (\> 5 mm and \< 8 mm above nerve conduit)
* Physical and mental condition that allow surgery and a 5-year follow-up period to be carried out without foreseeable problems
* Obtained informed consent from the patient

Specific criteria:

* Limited vertical space for implant placement, where conventional implants with lengths of more than 4 mm cannot be used
* Tooth loss or extraction at least 8 weeks before implant surgery
* Healthy implantation site
* Favorable and stable occlusal relationship
* Complete denture in the mandible. If no denture available, an interims prosthesis will be fitted
* Natural full dentition or sufficient complete or partial dentures in the maxilla

Exclusion Criteria

General criteria:

* Any conditions or circumstances which would interfere with the requirements for oral surgery
* Allergy to any metallic implant component
* Acute, untreated periodontitis
* Previous oro-maxillo-facial radiotherapy
* Any disorders in the planned implant area such as previous tumors or chronic bone disease (e.g., rheumatoid disease)
* Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc.)
* Alcohol or drug abuse
* Heavy smoking (\>10 cigarettes/day)
* Uncontrolled diabetes
* Severe bruxism or other destructive oral habits
* Pregnant or lactating women

Specific criteria:

* Need for a major bone regeneration technique
* Infections in adjacent tissue of the planned implantation site.
* Bleeding on probing (BOP) and plaque index (PI) higher 25%
* Insufficient bone volume in the posterior region for placing a Straumann Roxolid® / SLActive® 4mm short implant and in the interforaminal region for placing a Straumann Roxolid® / SLActive® implant with a minimum length of 10 mm determined by radiographic analysis (OPG)
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Straumann AG

UNKNOWN

Sponsor Role collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PV_4805

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bone Level Tapered Multi-Center Study
NCT02569671 ACTIVE_NOT_RECRUITING NA